Public Release: 

Access to investigational medicines for terminally ill through expanded access programs

JAMA Network Open

Bottom Line: A new study identified investigational medicines made available through expanded access programs for patients with life-threatening illnesses prior to approval from the U.S. Food and Drug Administration to assess the timing and duration of investigational drug availability.

Authors: Joseph S. Ross, M.D., M.H.S., of Yale University School of Medicine, New Haven, Connecticut, and coauthors

To Learn More: The full study is available on the For The Media website.

(doi:10.1001/jamanetworkopen.2018.0283)

Editor's Note: The article contains conflict of interest and funding support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

###

Want to embed a link to this study in your story?: Links will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2018.0283

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. Every Friday, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.